• Aliases: MetMAb, RO5490258
    • An IgG1 humanized monovalent mAb that is directed against MET by binding to the extracellular domain, preventing the binding of its ligand, HGF
    • Currently under investigation in phases 2 and 3 clinical trials in NSCLC and MET+ GE cancer
    • Recommended phase 2 dose: 15 mg/kg IV every 3 weeks
    • Half-life: 8 to 12 days
    • Common side effects: Fatigue, peripheral edema, nausea, hypoalbuminemia
    (Salgia et al., 2014)
    Other topics in Targeted and Immunotherapy Agents